Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

What is CAR-T Cell Therapy? CAR-T cell therapy represents a revolutionary approach in cancer treatment, utilizing genetically modified T cells to attack cancer cells. By inserting a chimeric antigen ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...